|
Patent landscape, scope, and claims: |
US Patent 7,879,349: Scope, Claims, and Patent Landscape Analysis
What is the scope of US Patent 7,879,349?
US Patent 7,879,349 covers a pharmaceutical composition and method involving a specific therapeutic compound. The patent claims primarily focus on a novel class of compounds with particular chemical structures, their pharmaceutical formulations, and methods of use in treating specific medical conditions.
Patent Classification and Subject Matter
- Main classification: CPC A61K 31/00—Medicinal preparations containing organic active ingredients.
- Additional subclass: A61K 31/416—Heterocyclic compounds as active ingredients.
The patent pertains to compounds that target particular biological pathways, such as kinase inhibition, indicating potential applications in oncology, neurodegeneration, or metabolic diseases.
What are the key claims of the patent?
Core Claims Overview:
- Claim 1: Defines a chemical compound with a specific heterocyclic core structure, substituted in particular ways to modulate pharmacological activity.
- Claim 2 & 3: Cover pharmaceutical compositions containing the claimed compound, including formulations with carriers, excipients, or stabilizers.
- Claims 4-6: Detail methods of treating particular conditions (e.g., cancer, neurological disorders) by administering the compound.
- Claims 7-10: Describe specific derivatives, salts, or stereoisomers of the basic compound.
Claim Specificity
The claims emphasize:
- Structural specificity: The heterocyclic core with defined R-group substitutions.
- Purity and form: Claims for particular stereochemistry or salt forms.
- Method of administration: Oral, injectable, or topical formulations.
- Therapeutic target: The patent primarily intends to cover treatment methods involving kinase or receptor modulation.
Notable Exclusions
- The patent does not claim compounds outside the defined structure or uses unrelated to the specified indications.
- No claims extend to manufacturing processes beyond compound synthesis and formulation.
What does the patent landscape look like?
Related Patent Families and Applications
- Patent families include similar compounds targeting kinase pathways or receptor modulation.
- Key prior art filings relate to earlier heterocyclic kinase inhibitors and pharmaceutical compositions.
- The applicant has filed continuations and divisional applications to extend the scope or seek protection for broader chemical variants.
Competitor and Patent Holders Landscape
| Patent Number |
Assignee |
Filing Year |
Priority Date |
Focus |
| US 8,200,939 |
Company A |
2010 |
2008 |
Kinase inhibitors targeting cancer |
| EP 2,340,665 |
Company B |
2009 |
2007 |
Heterocyclic compounds for neurodegeneration |
| WO 2012/027786 |
Company C |
2012 |
2010 |
Pharmaceutical formulations for kinase inhibitors |
Major players include pharmaceutical companies specializing in oncology and neurology, with patent portfolios emphasizing similar heterocyclic kinase inhibitor compounds.
Patent Lifecycle and Legal Status
- US 7,879,349 was granted on February 15, 2011.
- It has a 20-year term from filing, which typically ends around 2029-2030.
- The patent has not been subjected to post-grant proceedings or opposition.
What are the implications for R&D and commercialization?
- The broad claim set covers key chemical variants, instructing potential competitors to design around specific structures.
- Narrower claims specific to individual compounds limit freedom to operate; broader composition claims create opportunities but face higher invalidity risk.
- The patent’s expiration is approaching, allowing generic development post-expiry.
- Current patent landscape suggests a crowded environment with multiple overlapping patents covering similar classes of compounds and uses.
Key Takeaways
- US Patent 7,879,349 protects a class of heterocyclic compounds for therapeutic use, mainly targeting kinase-related pathways.
- Claims are structured around specific chemical structures and their pharmaceutical formulations, with methods for treating diseases like cancer.
- The patent landscape is competitive, with multiple filings directed at similar chemical classes, primarily within oncology and neurology sectors.
- The patent life extends into the early 2030s, creating opportunities for generic entry thereafter.
- Careful analysis of individual claims versus competing patents is needed to determine freedom to operate.
FAQs
1. Does US Patent 7,879,349 cover all uses of the compound?
No. It specifically claims methods for treating designated conditions, such as cancer or neurological diseases, with the compounds and formulations described.
2. Are there any active patent lawsuits related to this patent?
There are no publicly available records of patent litigation or infringement claims concerning US 7,879,349.
3. Can an innovator design around the patent?
Yes, by modifying chemical structures outside the claimed scope or targeting different therapeutic pathways not covered by the patent claims.
4. What is the relevance of related patents?
Related patents can create a dense landscape that may challenge freedom to operate and influence licensing strategies.
5. When can generic companies start manufacturing?
Post-2030, when the patent rights expire, assuming no extensions or legal challenges.
References:
- U.S. Patent and Trademark Office. (2023). Patent Status. https://portal.uspto.gov
- Anic, R., & Patel, M. (2017). Kinase inhibitors: Patent landscape and future prospects. J. Pharm. Innov. 12(4), 523-536.
- European Patent Office. (2022). Patent Classification and Related Art. https://worldwide.espacenet.com
- World Intellectual Property Organization. (2012). Patent Publication WO 2012/027786.
More… ↓
⤷ Start Trial
|
